Literature DB >> 12867031

Nuclei of adult mammalian somatic cells are directly reprogrammed to oct-4 stem cell gene expression by amphibian oocytes.

James A Byrne1, Stina Simonsson, Patrick S Western, John B Gurdon.   

Abstract

Nuclear reprogramming by the transplantation of somatic cell nuclei to eggs (in second meiotic metaphase) is always followed by a phase of chromosome replication and cell division before new gene expression is seen. To help understand the mechanism of nuclear reprogramming, we have asked whether the nuclei of normal, nontransformed, nondividing, and terminally differentiated mammalian cells can be directly reprogrammed, without DNA replication, by Xenopus oocytes. We find that nuclei of adult mouse thymocytes and of adult human blood lymphocytes, injected into Xenopus oocytes, are induced to extinguish a differentiation marker and to strongly express oct-4, the most diagnostic mammalian stem cell/pluripotency marker. In the course of 2 days at 18 degrees C, the mammalian oct-4 transcripts are spliced to mature mRNA. We conclude that normal mammalian nuclei can be directly reprogrammed by the nucleus (germinal vesicle) of amphibian oocytes to express oct-4 at a rate comparable to that of oct-4 in mouse ES cells. To our knowledge, this is the first demonstration of a stem cell marker being induced in a differentiated adult human cell nucleus. This is an early step toward the long-term aim of developing a procedure for reprogramming readily accessible human adult cells for cell replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12867031     DOI: 10.1016/s0960-9822(03)00462-7

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  66 in total

Review 1.  Hematopoietic stem cell transplantation: more than just hematopoietic?

Authors:  Alexandros Spyridonidis; Roland Mertelsmann; Jürgen Finke
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553

Review 2.  Nuclear reprogramming and stem cell creation.

Authors:  J B Gurdon; J A Byrne; S Simonsson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-14       Impact factor: 11.205

Review 3.  Delineating nuclear reprogramming.

Authors:  Jolene Ooi; Pentao Liu
Journal:  Protein Cell       Date:  2012-03-31       Impact factor: 14.870

4.  Recipient cell nuclear factors are required for reprogramming by nuclear transfer.

Authors:  Dieter Egli; Kevin Eggan
Journal:  Development       Date:  2010-05-12       Impact factor: 6.868

5.  The X and Y chromosomes assemble into H2A.Z-containing [corrected] facultative heterochromatin [corrected] following meiosis.

Authors:  Ian K Greaves; Danny Rangasamy; Michael Devoy; Jennifer A Marshall Graves; David J Tremethick
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 6.  Stem cell plasticity: the debate begins to clarify.

Authors:  Alexandros Spyridonidis; Robert Zeiser; Marie Follo; Yannis Metaxas; Jürgen Finke
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

7.  Stem cells: From embryology to cellular therapy? An appraisal of the present state of art.

Authors:  Sandro Eridani; Vittorio Sgaramella; Lidia Cova
Journal:  Cytotechnology       Date:  2004-03       Impact factor: 2.058

8.  Proteomic analysis of early reprogramming events in murine somatic cells incubated with Xenopus laevis oocyte extracts demonstrates network associations with induced pluripotency markers.

Authors:  Alex J Rathbone; Susan Liddell; Keith H S Campbell
Journal:  Cell Reprogram       Date:  2013-06-15       Impact factor: 1.987

9.  Skin keratinocytes pre-treated with embryonic stem cell-conditioned medium or BMP4 can be directed to an alternative cell lineage.

Authors:  K L Grinnell; J R Bickenbach
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

Review 10.  Transcriptional regulation of the Oct4 gene, a master gene for pluripotency.

Authors:  Steven Kellner; Nobuaki Kikyo
Journal:  Histol Histopathol       Date:  2010-03       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.